Anadolu Medical Center
Anadolu Medical Center
Turquie, Istanbul
Ilker Tinay
23 années d'expérience
accréditations :
La clinique est certifiée :
Le coût du traitement du cancer du rein en Turquie varie en fonction des procédures spécifiques et des besoins médicaux du patient. Les diagnostics initiaux, y compris les consultations avec des oncologues médicaux et des radiologues, varient de 190 € à 1 230 €. Pour les interventions chirurgicales, une néphrectomie radicale laparoscopique peut coûter environ 10 450 €, tandis qu"une chirurgie robotique plus avancée peut atteindre jusqu"à 22 780 €. De plus, une procédure de transplantation rénale est estimée à 18 030 €, incluant toutes les évaluations médicales nécessaires et le séjour à l"hôpital. Le plan de traitement global est adapté en fonction de l"état du patient et de l"évaluation détaillée par l"équipe médicale.
Le Pr Bülent Karagöz est spécialisé en biologie tumorale et en immunothérapie, avec plus de 20 ans d'expérience, traitant le cancer du rein au centre médical Anadolu.
Classé 3ème en Turquie pour l'oncologie – le Dr Tanrikulu apporte une expertise précise au traitement du cancer du rein au centre médical Anadolu.
Le Dr Solak apporte une formation spécialisée de l'Institut du cancer de l'Université Hacettepe et une vaste expérience dans divers types de cancers, y compris les cas de rein à l'hôpital Hisar Intercontinental.
Dr. Banu Atalar is a board-certified radiation oncologist (Türkiye, 2004). She is a Full Professor at Acibadem MAA University (2018–present) and a clinician at Anadolu Medical Center (2026–present). She trained at Istanbul and Cerrahpaşa. In 2011, she completed a Stanford clinical research fellowship in stereotactic radiosurgery. Her practice focuses on CNS, thoracic, and GI tumors. About 75% of her care involves SRS and MR‑guided adaptive SRS.
Her honors include the ASCO IDEA award (2004), the IASLC International Mentorship Award (2018), and H.FACR (2025). She has 72 international peer‑reviewed publications. Her leadership roles include President of the Turkish Society for Radiation Oncology (2025–27) and Chair of the ESTRO National Societies Committee (2024–27). She served on the ASCO Resource‑Stratified Guidelines Committee (2013–18) and on RSS meeting and nomination committees. She organized national congresses (2023, 2025) and has been an invited speaker at major meetings.
Turkey is a high-authority destination for kidney cancer care. Turkish medical centers report success rates up to 95% for kidney surgeries. Facilities utilize Da Vinci XI robotic systems and CyberKnife technology. JCI-accredited hospitals provide specialized teams with rapid access to treatment.
Bookimed Expert Insight: Anadolu Medical Center stands out because it employs over 250 specialized oncologists. This massive scale allows for highly specific sub-specialization in rare renal pathologies. Our data shows hospitals with this volume offer more refined tumor board reviews. This multidisciplinary approach is vital for complex stage 3 or 4 cases.
Patient Consensus: Patients often mention that having a dedicated translator makes the medical process stress-free. Many highlight the relief of moving from arrival to surgery in just a few days.
Turkish oncology centers utilize advanced surgical and systemic therapies for kidney cancer. Primary treatments include da Vinci robotic-assisted nephrectomy and laparoscopic surgery. Patients also access innovative targeted therapy and immunotherapy. High-precision radiation and CyberKnife technologies are standard for complex metastatic cases.
Bookimed Expert Insight: Anadolu Medical Center stands out because it is affiliated with Johns Hopkins Medicine. This brings American oncology protocols to Istanbul at a lower cost. Their multidisciplinary team approach ensures that surgeons and oncologists review every case together. This collaboration often leads to 15% better outcomes in complex cases. Some clinics also offer genomic profiling to tailor drug regimens.
Patient Consensus: Patients often mention the speed of starting treatment after their first arrival. They note that having translators and transfers included helps them focus on recovery.
Turkey reports a 90% to 94% 5-year survival rate for localized kidney cancer. Specialized centers achieve up to 100% technical success using cryotherapy for small tumors. Turkish facilities utilize the Da Vinci robotic system to maintain 95% surgical success rates for partial nephrectomies.
Bookimed Expert Insight: Turkish oncology centers like Anadolu Medical Center or Medipol often perform over 65,000 yearly operations. This massive volume allows surgeons to master robot-assisted partial nephrectomies. High-volume practice helps preserve kidney function while ensuring complete tumor removal.
Patient Consensus: Patients value the speed of diagnosis and the professionalism of Turkish medical teams. Many note that robotic options were available much sooner than in their home countries.